over antibody levels that can be achieved as well as concerns over the ability of older subjects to mount an effective immune response. The farthest advanced of these trails at the time of writing is the Elan/Wyeth trial of AAB-001 (bapineuzumab), which entered phase III testing in 2007 and uses a humanized monoclonal antibody directed against the N-terminus of Aβ. More information on this and other current clinical trials can be found at http://www.clinicaltrials.gov and http://alzforum.com.
